ストックスクリーナーアプリを入手
36.31
3.92%
1.37
アフターアワーズ：
36.31
Ideaya Biosciences Inc (IDYA) 最新ニュース
Truist Securities raises Ideaya Biosciences stock price target to $60 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News - Longbridge
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - Quantisnow
Buyback Watch: Can IDEAYA Biosciences Inc 30J stock ride next bull market cycleJuly 2025 Movers & AI Powered Trade Plan Recommendations - moha.gov.vn
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Nasdaq 100 Index Research-Driven Model - Kalkine Media
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA) - MarketBeat
Will IDEAYA Biosciences Inc. stock benefit from commodity pricesCandlestick Trading Patterns & Next-Level Stock Intelligence, Now Free - bollywoodhelpline.com
IDEAYA Biosciences Earnings Notes - Trefis
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers - Nasdaq
Will IDEAYA Biosciences Inc. stock rally after Fed decisions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
How IDEAYA Biosciences Inc. (30J) stock compares with tech leaders2025 Technical Patterns & Community Supported Trade Ideas - Улправда
Why IDEAYA Biosciences Inc. stock attracts high net worth investorsJuly 2025 Price Swings & Weekly High Return Stock Opportunities - Улправда
Aug EndMonth: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsStock Surge & Accurate Trade Setup Notifications - Улправда
Why IDEAYA Biosciences Inc. stock appeals to dividend seekersQuarterly Profit Summary & Precise Swing Trade Alerts - Улправда
How interest rate cuts could boost IDEAYA Biosciences Inc. stockChart Signals & Consistent Return Investment Signals - Улправда
Gap Down: Will IDEAYA Biosciences Inc. stock outperform growth indexesJuly 2025 Update & Expert-Curated Trade Recommendations - Улправда
How buybacks impact IDEAYA Biosciences Inc. stock valueJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
Why IDEAYA Biosciences Inc. (30J) stock remains top ratedPortfolio Return Summary & AI Powered Buy and Sell Recommendations - DonanımHaber
How supply shortages influence IDEAYA Biosciences Inc. (30J) stockJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Aug Weekly: Why IDEAYA Biosciences Inc. stock attracts high net worth investorsTrade Signal Summary & Weekly Momentum Picks - Улправда
Will IDEAYA Biosciences Inc. stock outperform growth indexesMarket Rally & Accurate Entry/Exit Alerts - Улправда
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies - GlobeNewswire Inc.
IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress - simplywall.st
Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial - Yahoo Finance
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com Australia
Ideaya Biosciences to regain rights for two programs as GSK ends partnership By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ: IDYA) outlines GSK exit, program transfer and cash runway - Stock Titan
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial - Investing.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com South Africa
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
IDEAYA Biosciences submits IND for novel cancer drug IDE574 - Investing.com India
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView — Track All Markets
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers – Company Announcement - Financial Times
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
GSK cuts the cord on Ideaya collaboration, letting go of 2 programs - Fierce Biotech
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week HighHere's Why - MarketBeat
Federated Hermes Inc. Has $97.27 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):